* Ratio is calculated based on latest financial & current share price.
(All Amount in INR Millions)
(All Amount in INR Millions)
(All Amount in INR Millions)
India’s digital consumer healthcare app, PharmEasy is referred to as a super app, offering customers on-demand access to home delivery for a comprehensive range of prescriptions and OTC pharmaceuticals. The company provides consumer healthcare products, information, consultations, and diagnostics tests from renowned laboratories. The company has collaborated with trusted doctors and registered in-store pharmacies. Incorporated in 2015, PharmEasy is currently have more than 25 million users. Moreover, with a market capitalization of approximately ₹300 crores, PharmEasy unlisted shares are presently a whizz among investors and financial advisors.
Established by Dharmil Seth and Dr Dhaval Shah, PharmEasy serves every habitable zip code. The authorised share capital of the company is Rs. 1031.08 Cr and the total paid up capital is Rs. 619.69 Cr. The initial idea of the company was to give end users an online pharmacy, but with the inclusion of consultation from trusted doctors and diagnostic tests from renowned laboratories, the application turned out to be quintessential. Furthermore, the company closed a revenue of ₹57,288.21 crores in the fiscal year 2022 opposed to Rs. 2,335 crores in 2021.
Ebbs and flow is a part of every company and in the previous years, almost every firm hit its all-time low, and so was PharmEasy. However, India’s largest digital healthcare platform boasts the potential to overcome its low. PharmEasy share price experienced a hike during November and December of 2021. After this year, the share price of the company started declining and reached a range varying between ₹30 – ₹40 per share price, which is now ₹22. Additionally, with over 2.4 million transacting consumers, PharmEasy saw a 2.5X more operating revenue last year.
Despite the growth in profitability, PharmEasy share price has another take in the market. Pharmacy’s unlisted share price witnessed a decline of Rs. 22 in April 2023 and fell to Rs. 12 per equity share in October 2023. The main reason behind this is negative cash flow and EBITDA (Earnings before interest, taxes, depreciation, and amortisation). Another reason behind it was the setback was the disrupted IPO market.
Total no. of shares available | 10000 |
Face Value per share | ₹ 1 Per Equity Share |
ISIN | INE0DJ201029 |
Lot Size | 500 Shares |
Current Price per share | ₹ 12.3 per Equity Share |
PharmEasy received its first funding in the year 2016 and joined hands with Ascent Health and five other firms to form the most effective digital healthcare platform in India – API Holdings. Presently, the company has a face value of ₹ 1 per equity share and comprising a lot size of 150 unlisted shares.
PharmEasy emerged as the most prominent name in the industry after its merger in 2020. With API Holdings as the parent company, PharmEasy is determined to show a staging growth rate, and investors are anticipating nothing less from the firm. Its parent company witnessed a total income which was more than double to $714 million in the fiscal year 2022. Moreover, PharmEasy share price today is ₹22 per share. Though the PharmEasy stock price witnessed a low in the last few months, the data below clearly depicts that investors are not ready to sell their PharmEasy unlisted shares, further indicating their belief in the growth.
Apart from the great face & brand value, and investor’s belief, another reason for investing in PharmEasy is the stunning revenue generated by the company. Look at the company’s data given below:
From the above data, the growth of PharmEasy unlisted share price can be clearly anticipated to go up. Further, reports suggest that the platform expects to raise $200 million from its investors and revenue with an annual rate of 18.1% till the end of 2023. Thus, if you want to invest and earn, now is the time! PharmEasy unlisted shares are currently one of the best options for your investment portfolio.
In 2023, PharmEasy made developmental changes and took steps to increase its profitability share in the market. It has significantly reduced its marketing & growth expense from 7.9% to 3.3% of revenue in 2023. As a result, the company’s total marketing expenses fell to Rs. 201 crores. Moving to its EBITDA (Earnings before interest, taxes, depreciation, and amortisation) margin, the rates improved from -13.6% to -8.4% in FY 2023.
PharmEasy strategically focuses on increasing its share of margin accretive private labels during the period of FY 2022-23. Additionally, it developed a focus on investing to scale up its cross-sell capabilities to get high-margin services for customers. For the fiscal year 2023, almost 50 lakh customers, which constitutes 13.8% of the total PharmEasy consumer base, avail their diagnostic services.
Buying PharmEasy unlisted shares is pretty easy, especially with Stockify. We are here with an ensemble of details such as Key Performance Indicators, revenue growth, EBITDA margin reports, EPS growth, etc. Moreover, the expert stock brokers at Stockify constantly keep track of the trends and changes in the PharmEasy unlisted shares price, and update prices as per the market fluctuation daily.
PharmEasy stock price is currently the talk of the town. Analyse and compare the key indicators, figure out your requirements and rely on our experts to guide you throughout the PharmEasy unlisted shares buying process. We will take care of everything – from guidance to documentation.
PharmEasy company share price is updated every day at Stockify. Our experts stay updated with stock market trends and keep a close eye on PharmEasy stock price fluctuations and immediately update prices as per the market trends on a daily basis. If you are interested in buying PharEasy Unlisted Shares, connect with us and stay tuned with our prices.
You can subscribe to our newsletter to get regular updates regarding PharmEasy share price, market trends, and other indicators which assist in determining whether or not a share is beneficial for your portfolio. PharmEasy unlisted share price India is ₹22.
For those who want to cope with market fluctuation, portfolio diversification is paramount for them. Diversification is a vital way to minimise the blow that hits while the market goes down. Stockify brings a list of unlisted shares from top-rated Pre-IPO companies at authentic prices. Apart from buying and selling PharmEasy unlisted shares, you can also check the best unlisted shares in India. We bring you unlisted shares from all the sectors – IT, energy, healthcare, insurance, technology, finance, manufacturing, and many more. Take a look at the PharmEasy share price today and also glance up other unlisted shares hosted by Stockify, as specified below:
Reliance Retail, boAT Unlisted Shares, Chennai Super Kings, Anglo-French Drugs & Industries, Hexaware Technologies Ltd, Five Star Business Finance Ltd Unlisted Shares, Fincare Small Finance Bank Ltd Unlisted Shares, Arohan Financial Services Unlisted Shares, Utkarsh Coreinvest Ltd Unlisted Shares, Fino Paytech Ltd Unlisted Shares, Hero Fincorp Ltd Unlisted Shares, National Stock Exchange Ltd Nse Unlisted Shares, National Commodity Derivatives Exchange Ltd Ncdex Unlisted Shares, MetroPolitan Stock Exchange MSEI Unlisted Shares, Capital, Small Finance Bank Ltd Unlisted Shares, and Motilal Oswal Home Finance Ltd Unlisted Shares.